Dr. Wiernikowski is the current President of the International Society of Oncology Pharmacy Practitioners.
Essential medicines for pediatric oncology in developing countries†
Article first published online: 28 FEB 2013
Copyright © 2013 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 60, Issue 5, pages 889–891, May 2013
How to Cite
Mehta, P. S., Wiernikowski, J. T., Petrilli, J. A. S., Barr, R. D. and for the Working Group on Essential Medicines of the Pediatric Oncology in Developing Countries committee of SIOP (2013), Essential medicines for pediatric oncology in developing countries. Pediatr. Blood Cancer, 60: 889–891. doi: 10.1002/pbc.24476
- Issue published online: 14 MAR 2013
- Article first published online: 28 FEB 2013
- Manuscript Accepted: 26 DEC 2012
- Manuscript Received: 5 NOV 2012
- pediatric oncology;
- support care;
- quality of life
The burden of cancer in children in low and middle income countries (LMICs) is substantial, comprising at least 80% of incident cases globally, and an even higher proportion of cancer-related deaths. With survival rates exceeding 80% in high income countries, it is imperative to transfer these successes to LMICs. A major challenge is the poor availability of safe, cost-effective chemotherapy. A list of 51 drugs—chemotherapeutics, infectious disease agents, and supportive care medications—is proposed as essential to improving the survival of children with cancer in LMICs with an additional 13 drugs identified as being of further value. Pediatr Blood Cancer 2013; 60: 889–891. © 2013 Wiley Periodicals, Inc.